Featured Publications
Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, Bui D, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Bajema K. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation. Annals Of Internal Medicine 2023, 176: 1486-1497. PMID: 37903369, PMCID: PMC10620954, DOI: 10.7326/m23-1394.Peer-Reviewed Original ResearchConceptsAcute COVID-19Veterans Health AdministrationUntreated comparatorsThromboembolic eventsCOVID-19Severe COVID-19Target trial emulationSARS-CoV-2Post COVID-19 conditionIndex dateVenous thromboembolismBaseline characteristicsCumulative incidencePulmonary embolismAcute infectionMedian ageOral antiviralsTrial emulationVHA careOutpatient treatmentInternational ClassificationHealth AdministrationU.S. veteransVeterans AffairsOrgan systemsAnti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
Yan L, Streja E, Li Y, Rajeevan N, Rowneki M, Berry K, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023. JAMA Network Open 2023, 6: e2331249. PMID: 37651140, PMCID: PMC10472184, DOI: 10.1001/jamanetworkopen.2023.31249.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapyVeterans Health AdministrationVeterans Integrated Service NetworkSARS-CoV-2Higher Charlson Comorbidity Index scoresCharlson Comorbidity Index scoreNon-Hispanic veteransComorbidity Index scoreProportion of patientsSymptomatic COVID-19Multivariable logistic regressionCOVID-19 vaccinationCohort studyMedicare databaseVHA careUS veteransMAIN OUTCOMEMedical conditionsHispanic veteransPharmacotherapyHealth AdministrationIndex scoreCommunity careNonhospitalized personsWhite veteransEffectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Bajema K, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, Yan L, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Ioannou G. Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Annals Of Internal Medicine 2023, 176: m22-3565. PMID: 37276589, PMCID: PMC10243488, DOI: 10.7326/m22-3565.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationCOVID-19 symptom onsetCOVID-19-related outcomesSevere COVID-19Six-month outcomesCOVID-19 vaccinationCOVID-19 treatmentCOVID-19SARS-CoV-2Percent of participantsUntreated control participantsCause mortalitySymptom onsetMedian ageOral antiviralsVHA careOutpatient treatmentHospitalizationHealth AdministrationDay 31U.S. veteransVariant transmissionMost veteransVeterans AffairsOne monthEarly Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022
Bajema K, Wang X, Hynes D, Rowneki M, Hickok A, Cunningham F, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Viglianti E, Streja E, Yan L, Aslan M, Huang G, Ioannou G. Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022. JAMA Network Open 2022, 5: e2241434. PMID: 36367727, PMCID: PMC9652752, DOI: 10.1001/jamanetworkopen.2022.41434.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapySevere COVID-19SARS-CoV-2Health care systemCohort studyRisk factorsCare systemMedical conditionsCOVID-19Positive SARS-CoV-2 testVeterans Affairs Health Care SystemCOVID-19-related hospitalizationCOVID-19-related symptomsLarge integrated health care systemSARS-CoV-2 testVA health care systemIntegrated health care systemNon-Hispanic veteransModerate COVID-19Odds of receiptMultivariable logistic regressionCOVID-19 vaccinationMedical comorbiditiesMedian ageAnti-SARS
2024
Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer
Sun J, Tian T, Wang N, Jing X, Qiu L, Cui H, Liu Z, Liu J, Yan L, Li D. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer. Frontiers In Endocrinology 2024, 15: 1338420. PMID: 38384968, PMCID: PMC10880016, DOI: 10.3389/fendo.2024.1338420.Peer-Reviewed Original ResearchConceptsHigh-volume diseasePresence of bone metastasesSerum sialic acidBone metastasesProstate-specific antigenProstate cancer patientsProstate cancerArea under the curveCut-off valueReceiver operating characteristicAssociated with high volume diseasePredictors of bone metastasisLevels of serum sialic acidClinical parameters of patientsDiagnosis of prostate cancerMetastasis of prostate cancerReceiver operating characteristic curve analysisBone metastasis of prostate cancerDiagnosed PCa patientsMultivariate logistic regression analysisSerum SA levelsMann-Whitney U testParameters of patientsLogistic regression analysisLevels of alkaline phosphatase